Scpharmaceuticals Historical Income Statement
| SCPH Stock | USD 3.04 0.03 1.00% |
Historical analysis of Scpharmaceuticals income statement accounts such as Gross Profit of 26.2 M, Other Operating Expenses of 106.2 M, Research Development of 16.4 M or Cost Of Revenue of 11.9 M can show how well Scpharmaceuticals performed in making a profits. Evaluating Scpharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Scpharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Scpharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Scpharmaceuticals is a good buy for the upcoming year.
Scpharmaceuticals |
About Scpharmaceuticals Income Statement Analysis
Scpharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Scpharmaceuticals shareholders. The income statement also shows Scpharmaceuticals investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Scpharmaceuticals Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Scpharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Scpharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.As of now, Scpharmaceuticals' Other Operating Expenses is increasing as compared to previous years. The Scpharmaceuticals' current Research Development is estimated to increase to about 16.4 M, while Depreciation And Amortization is projected to decrease to under 19 K.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Expense | 3.3M | 8.1M | 7.6M | 3.8M | Depreciation And Amortization | 468K | 626K | 20K | 19K |
Scpharmaceuticals income statement Correlations
Click cells to compare fundamentals
Scpharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Scpharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 399K | 438K | 468K | 626K | 20K | 19K | |
| Interest Expense | 2.6M | 2.6M | 3.3M | 8.1M | 7.6M | 3.8M | |
| Selling General Administrative | 11.8M | 9.8M | 20.6M | 53.4M | 77.6M | 81.5M | |
| Gross Profit | (399K) | (438K) | (468K) | 9.8M | 25.0M | 26.2M | |
| Other Operating Expenses | 29.9M | 25.8M | 36.2M | 69.0M | 101.1M | 106.2M | |
| Operating Income | (29.9M) | (25.8M) | (36.2M) | (55.4M) | (64.8M) | (61.5M) | |
| Net Income From Continuing Ops | (32.2M) | (28.0M) | (36.8M) | (50.2M) | (85.1M) | (80.9M) | |
| Ebit | (29.6M) | (25.5M) | (33.5M) | (46.7M) | (77.6M) | (73.7M) | |
| Research Development | 18.1M | 16.0M | 15.5M | 11.8M | 12.1M | 16.4M | |
| Ebitda | (29.2M) | (25.0M) | (33.1M) | (46.1M) | (77.6M) | (73.7M) | |
| Cost Of Revenue | 399K | 438K | 468K | 3.8M | 11.4M | 11.9M | |
| Total Operating Expenses | 29.9M | 25.8M | 36.2M | 65.2M | 89.7M | 94.2M | |
| Income Before Tax | (32.2M) | (28.0M) | (36.8M) | (54.8M) | (85.1M) | (80.9M) | |
| Total Other Income Expense Net | (2.3M) | (2.2M) | (681K) | 586K | (20.4M) | (19.4M) | |
| Net Income Applicable To Common Shares | (33.0M) | (32.2M) | (28.0M) | (36.8M) | (33.2M) | (34.8M) | |
| Net Income | (34.4M) | (30.5M) | (37.5M) | (54.8M) | (85.1M) | (80.9M) | |
| Income Tax Expense | 2.2M | 2.5M | 681K | 458.1K | 412.3K | 391.7K | |
| Net Interest Income | (2.3M) | (2.5M) | (2.1M) | (3.2M) | (4.1M) | (3.9M) | |
| Interest Income | 315K | 49K | 1.2M | 4.8M | 3.4M | 3.6M | |
| Reconciled Depreciation | 399K | 438K | 468K | 606K | 20K | 19K | |
| Non Operating Income Net Other | 1.7M | 311K | 364K | 2.6M | 3.0M | 3.2M |
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share | Quarterly Revenue Growth 0.993 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.